| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11497709 | THERAPEUTICSMD INC | NA |
Nov, 2032
(9 years from now) | |
| US10537581 | THERAPEUTICSMD INC | Vaginal inserted estradiol pharmaceutical compositions and methods |
Nov, 2032
(9 years from now) | |
| US11246875 | THERAPEUTICSMD INC | Vaginal inserted estradiol pharmaceutical compositions and methods |
Nov, 2032
(9 years from now) | |
| US11241445 | THERAPEUTICSMD INC | Vaginal inserted estradiol pharmaceutical compositions and methods |
Nov, 2032
(9 years from now) | |
| US10835487 | THERAPEUTICSMD INC | Vaginal inserted estradiol pharmaceutical compositions and methods |
Nov, 2032
(9 years from now) | |
| US9289382 | THERAPEUTICSMD INC | Vaginal inserted estradiol pharmaceutical compositions and methods |
Nov, 2032
(9 years from now) | |
| US10806697 | THERAPEUTICSMD INC | Vaginal inserted estradiol pharmaceutical compositions and methods |
Nov, 2032
(9 years from now) | |
| US11351182 | THERAPEUTICSMD INC | Vaginal inserted estradiol pharmaceutical compositions and methods |
Nov, 2032
(9 years from now) | |
| US11304959 | THERAPEUTICSMD INC | Vaginal inserted estradiol pharmaceutical compositions and methods |
Nov, 2032
(9 years from now) | |
| US10568891 | THERAPEUTICSMD INC | Vaginal inserted estradiol pharmaceutical compositions and methods |
Jun, 2033
(9 years from now) | |
| US11123283 | THERAPEUTICSMD INC | Soluble estradiol capsule for vaginal insertion |
Jun, 2033
(9 years from now) | |
| US10888516 | THERAPEUTICSMD INC | Soluble estradiol capsule for vaginal insertion |
Jun, 2033
(9 years from now) | |
| US10471072 | THERAPEUTICSMD INC | Vaginal inserted estradiol pharmaceutical compositions and methods |
Jun, 2033
(9 years from now) | |
| US11116717 | THERAPEUTICSMD INC | Soluble estradiol capsule for vaginal insertion |
Jun, 2033
(9 years from now) | |
| US11065197 | THERAPEUTICSMD INC | Soluble estradiol capsule for vaginal insertion |
Jun, 2033
(9 years from now) | |
| US10668082 | THERAPEUTICSMD INC | Vaginal inserted estradiol pharmaceutical compositions and methods |
Jun, 2033
(9 years from now) | |
| US10258630 | THERAPEUTICSMD INC | Vaginal inserted estradiol pharmaceutical compositions and methods |
Dec, 2033
(10 years from now) | |
| US10398708 | THERAPEUTICSMD INC | Vaginal inserted estradiol pharmaceutical compositions and methods |
Dec, 2033
(10 years from now) | |
| US9180091 | THERAPEUTICSMD INC | Soluble estradiol capsule for vaginal insertion |
Dec, 2033
(10 years from now) | |
| US11266661 | THERAPEUTICSMD INC | Vaginal inserted estradiol pharmaceutical compositions and methods |
Feb, 2034
(10 years from now) | |
Imvexxy is owned by Therapeuticsmd Inc.
Imvexxy contains Estradiol.
Imvexxy has a total of 20 drug patents out of which 0 drug patents have expired.
Imvexxy was authorised for market use on 29 May, 2018.
Imvexxy is available in insert;vaginal dosage forms.
Imvexxy can be used as treatment of dyspareunia; treatment of a symptom of vulvar and vaginal atrophy, treatment of a symptom of vulvar and vaginal atrophy; treatment of moderate to severe dyspareunia, treatment of a symptom of vulvar and vaginal atrophy; treatment of dyspareunia.
The generics of Imvexxy are possible to be released after 02 February, 2034.
Drugs and Companies using ESTRADIOL ingredient
Market Authorisation Date: 29 May, 2018
Treatment: Treatment of dyspareunia; Treatment of a symptom of vulvar and vaginal atrophy; Treatment of moderate to severe dyspareunia
Dosage: INSERT;VAGINAL
IMVEXXY family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic